Encompass Health Corporation Common Stock EHC

Zacks Investment Research 12 nov

Encompass Health Corporation, a provider of integrated healthcare services with 173 hospitals across 39 states and Puerto Rico, has been identified as a momentum stock worth watching. The company holds a Zacks Rank #2 (Buy) rating with a VGM Score of A and Momentum Style Score of B. Six analysts revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $6.23 per share for fiscal 2026. Shares are up 12.4% over the past four weeks, and the company boasts an average earnings surprise of +8.5%.

Zacks Investment Research 5 nov

BrightSpring Health Services (BTSG) shares jumped 11.3% following strong Q3 results with revenues up 26.4% to $4.21B and adjusted EPS surging 80%. The company raised its 2026 guidance, but its elevated 30.9X forward P/E valuation leaves limited room for execution errors. While specialty pharmacy growth and margin expansion support the rally, sustained earnings delivery and successful margin conversion remain critical for future gains.

Zacks Investment Research 2 nov

Encompass Health (EHC) has earned a Zacks Momentum Style Score of A and a #2 (Buy) rating, driven by strong short-term price performance outpacing its industry peers and positive earnings estimate revisions. The stock has gained 9.52% over the past week and 19.37% over the past year, significantly outperforming the S&P 500.

Zacks Investment Research 30 oct

The stock market closed with mixed results as technology stocks declined while healthcare, consumer staples, and financial sectors showed strength. Encompass Health (EHC) was highlighted as a stock to watch with a #2 Buy rating and strong Style Scores.

Zacks Investment Research 28 oct

Encompass Health reported Q3 2026 revenue of $1.61 billion, up 8.9% year-over-year, beating consensus estimates by 0.63%. EPS came in at $1.52, exceeding the consensus estimate of $1.38 by 10.15%. Key metrics showed net patient revenue per discharge of $22,543 (above estimates) and inpatient revenues up 9.9% year-over-year, though discharges slightly missed expectations and other operating revenues declined 19.5%. The stock holds a Zacks Rank #3 (Hold) rating and has underperformed the broader market over the past month.